论文部分内容阅读
目的:观察西妥昔单抗联合化疗治疗晚期结直肠癌的有效性、安全性和对生活质量的影响。方法:2006-11-2009-02,我院共有11例患者,均经病理组织学确诊为晚期转移性结直肠癌,联合FOLFIRI或FOLFOX方案治疗,西妥昔单抗首剂400mg/m2,以后每周250mg/m2维持。结果:11例患者治疗后3例CR,1例PR,6例SD,1例PD,有效率36.4%,疾病控制率90.9%。主要的不良反应为痤疮样皮疹,治疗后生活质量改善较好。结论:西妥昔单抗联合化疗治疗晚期转移性结直肠癌有效,除皮疹外,并未增加化疗的毒副反应,治疗后生活质量较好。
Objective: To observe the efficacy, safety and quality of life of cetuximab plus chemotherapy in the treatment of advanced colorectal cancer. METHODS: From November 2006 to February 2009, 11 patients in our hospital were diagnosed as advanced metastatic colorectal cancer by histopathology. After treatment with FOLFIRI or FOLFOX regimen, the first dose of cetuximab was 400mg / m2. 250mg / m2 weekly maintenance. Results: After treatment, 3 cases of CR, 1 case of PR, 6 cases of SD and 1 case of PD had an effective rate of 36.4% and a disease control rate of 90.9%. The main adverse reaction was an acne-like rash, which improved the quality of life after treatment. Conclusion: Cetuximab combined with chemotherapy is effective in treating advanced metastatic colorectal cancer. In addition to the rash, the side effects of chemotherapy are not increased, and the quality of life after treatment is better.